In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

AbbVie recently signed a definitive agreement to acquire privately held biotech Capstan Therapeutics for a total deal value ...

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

We came across a bullish thesis on AbbVie Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie will also acquire Capstan’s CellSeeker tLNP platform technology, which is designed to deliver RNA payloads, such as ...

Healthcare giants AbbVie and Abbott Laboratories are both Dividend Kings. In 2013, AbbVie (NYSE: ABBV) became a publicly ...

AbbVie is a Dividend King with solid growth prospects. Enbridge is a leading pipeline operator and natural gas utility with ...

Two of the world’s largest pharmaceutical companies are suing Oklahoma to stop a new state law dealing with a $70 billion ...